$10.29 Million in Sales Expected for Seres Therapeutics Inc (NASDAQ:MCRB) This Quarter

Brokerages expect Seres Therapeutics Inc (NASDAQ:MCRB) to report $10.29 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Seres Therapeutics’ earnings, with the lowest sales estimate coming in at $9.26 million and the highest estimate coming in at $11.90 million. Seres Therapeutics posted sales of $4.61 million in the same quarter last year, which suggests a positive year over year growth rate of 123.2%. The business is scheduled to report its next earnings report on Thursday, August 1st.

On average, analysts expect that Seres Therapeutics will report full year sales of $30.87 million for the current fiscal year, with estimates ranging from $22.32 million to $35.20 million. For the next fiscal year, analysts expect that the business will post sales of $39.68 million, with estimates ranging from $18.70 million to $56.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.12). The firm had revenue of $7.32 million for the quarter, compared to analysts’ expectations of $8.61 million. Seres Therapeutics had a negative net margin of 301.60% and a negative return on equity of 1,583.95%.

Several equities analysts recently commented on the stock. BidaskClub raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. Jefferies Financial Group assumed coverage on shares of Seres Therapeutics in a research report on Tuesday, April 30th. They issued a “hold” rating and a $7.00 price objective for the company. Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research report on Wednesday, May 8th. Oppenheimer reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, March 19th. Finally, ValuEngine lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 10th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $11.13.

In related news, Director Noubar Afeyan acquired 8,888,888 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The stock was purchased at an average cost of $2.25 per share, with a total value of $19,999,998.00. Following the transaction, the director now directly owns 15,141 shares of the company’s stock, valued at approximately $34,067.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 37.00% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in Seres Therapeutics during the 1st quarter valued at approximately $842,000. ARK Investment Management LLC grew its stake in Seres Therapeutics by 28.4% during the 1st quarter. ARK Investment Management LLC now owns 5,287,713 shares of the biotechnology company’s stock valued at $36,327,000 after purchasing an additional 1,168,234 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Seres Therapeutics by 21.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 3,500 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in Seres Therapeutics during the 1st quarter valued at approximately $5,504,000. Finally, Alpine Woods Capital Investors LLC acquired a new stake in Seres Therapeutics during the 1st quarter valued at approximately $412,000. 82.03% of the stock is owned by hedge funds and other institutional investors.

MCRB stock opened at $3.22 on Friday. The stock has a market capitalization of $118.37 million, a price-to-earnings ratio of -1.33 and a beta of 2.20. The firm’s 50-day moving average price is $3.47. Seres Therapeutics has a one year low of $2.02 and a one year high of $9.35.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Recommended Story: How to identify percentage decliners

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.